Taysha Gene Therapies, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Taysha Gene Therapies, Inc. (TSHA) reported Increase (Decrease) in Prepaid Expense and Other Assets of $1.44 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- Taysha Gene Therapies, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $645.00K.
- Taysha Gene Therapies, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $794.00K, a 24.52% decline year-over-year.
- Taysha Gene Therapies, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $2.13M.
- Taysha Gene Therapies, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$971.00K, a 231.04% decline year-over-year.
- Taysha Gene Therapies, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $1.73M.
- Taysha Gene Therapies, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$207.00K.
- Taysha Gene Therapies, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$6.01M.
- Taysha Gene Therapies, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$2.09M, a 162.12% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $645.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.44M 10-Q · filed 2026-08-11 | $3.57M derived: sum of 3 quarters · filed 2026-08-11 | $2.60M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $794.00K 10-Q · filed 2026-05-06 | $2.93M derived: sum of 2 quarters · filed 2026-05-06 | $1.96M derived: sum of 3 quarters · filed 2026-05-06 | $1.48M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.16M derived: sum of 2 quarters · filed 2026-03-19 | $682.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.73M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$971.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$1.45M derived: sum of 2 quarters · filed 2026-08-11 | -$401.00K 10-Q · filed 2025-11-04 | -$1.22M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$482.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $570.00K 10-Q · filed 2026-08-11 | -$249.00K derived: sum of 3 quarters · filed 2026-08-11 | $492.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.05M 10-Q · filed 2026-05-06 | $233.00K derived: sum of 2 quarters · filed 2026-05-06 | $974.00K derived: sum of 3 quarters · filed 2026-05-06 | $152.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$819.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$78.00K derived: sum of 2 quarters · filed 2026-03-19 | -$900.00K derived: sum of 3 quarters · filed 2026-03-19 | -$207.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $741.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$81.00K derived: sum of 2 quarters · filed 2025-11-04 | $612.00K 10-Q · filed 2025-11-04 | -$1.39M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$822.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$129.00K 10-Q · filed 2025-08-12 | -$2.13M derived: sum of 3 quarters · filed 2025-08-12 | -$5.63M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $693.00K 10-Q · filed 2025-05-15 | -$1.31M derived: sum of 2 quarters · filed 2025-05-15 | -$4.81M derived: sum of 3 quarters · filed 2025-05-15 | -$5.72M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$5.50M derived: sum of 2 quarters · filed 2025-02-26 | -$6.41M derived: sum of 3 quarters · filed 2025-02-26 | -$6.01M 10-K · filed 2025-02-26 |
| 2023-09-30 | -$3.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$4.41M derived: sum of 2 quarters · filed 2024-11-13 | -$4.01M 10-Q · filed 2024-11-13 | -$4.12M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$909.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$509.00K 10-Q · filed 2024-08-12 | -$617.00K derived: sum of 3 quarters · filed 2024-08-12 | -$2.52M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $400.00K 10-Q · filed 2024-05-14 | $292.00K derived: sum of 2 quarters · filed 2024-05-14 | -$1.61M derived: sum of 3 quarters · filed 2024-05-14 | -$1.42M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$2.01M derived: sum of 2 quarters · filed 2024-03-19 | -$1.82M derived: sum of 3 quarters · filed 2024-03-19 | -$2.09M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$1.71M derived: sum of 2 quarters · filed 2023-11-14 | -$1.98M 10-Q · filed 2023-11-14 | -$149.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $191.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$80.00K 10-Q · filed 2023-08-14 | $1.75M derived: sum of 3 quarters · filed 2023-08-14 | -$1.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$271.00K 10-Q · filed 2023-05-11 | $1.56M derived: sum of 2 quarters · filed 2023-05-11 | -$192.00K derived: sum of 3 quarters · filed 2023-05-11 | -$1.09M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $79.00K derived: sum of 2 quarters · filed 2023-03-28 | -$823.00K derived: sum of 3 quarters · filed 2023-03-28 | $3.36M 10-K · filed 2023-03-28 |
| 2021-09-30 | -$1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$2.65M derived: sum of 2 quarters · filed 2022-11-08 | $1.53M 10-Q · filed 2022-11-08 | $7.51M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$902.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $3.28M 10-Q · filed 2022-08-11 | $9.26M derived: sum of 3 quarters · filed 2022-08-11 | $9.86M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $4.18M 10-Q · filed 2022-05-16 | $10.16M derived: sum of 2 quarters · filed 2022-05-16 | $10.76M derived: sum of 3 quarters · filed 2022-05-16 | $10.77M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $5.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $6.58M derived: sum of 2 quarters · filed 2022-03-31 | $6.58M derived: sum of 3 quarters · filed 2022-03-31 | $6.58M 10-K · filed 2022-03-31 |
| 2020-09-30 | $595.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $604.00K derived: sum of 2 quarters · filed 2021-11-10 | $604.00K 10-Q · filed 2021-11-10 | $604.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $9.00K 10-Q · filed 2021-08-16 | $9.00K derived: sum of 3 quarters · filed 2021-08-16 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $0.00 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |